Mon, Mar 2, 2015, 10:48 AM EST - U.S. Markets close in 5 hrs 12 mins


% | $
Quotes you view appear here for quick access.

pSivida Corp. Message Board

  • mofisher22 mofisher22 Jul 7, 2013 8:11 PM Flag

    Question of the informed longs on Iluvien

    I know there are lots of newbies here from the past few weeks and more will come in the coming weeks. Could one or more of you 3 or 4 well informed guys clarify what it has been approved for in Europe, the patient population, and what the Oct, FDA will deal with here in USA. I understand that the previous rejections were due to asking forapproval for the entire potential market, but now they are only requesting for a subset that has not responded to other available treatment. And in Europe, is it also only targeted for that same group? Also, any other catalysts thru the end of 2013? Any other info also that could bring newbies up to date on PSDV. For newbies, if you scroll back on this board,you will see about 3 or 4 posters who have been here for a year or maybe 2 or 3, and you can learn a lot from reading their posts, and I believe they will add some good info on this thread. Like PSDV sp, we long time posters have been just taking a break, getting ready for next leg up.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I'm one of the newbies who just bought in today at the close and found this to be a very informative thread. Thanks everybody for sharing what you know about pSivida. I like what i've seen so far with this company and am looking to some positive movement upwards by year's end. Hope I wasn't too late in jumping on board! Good luck to all!

      Sentiment: Strong Buy

    • Mo:
      Here's the deal. September will be big for us because speculative investors will take a shot (at least a double) that the FDA will approve Illuvien. Been there and seen it before .No guarantees but all indicators are that ALIM has finally focused on those patients who have no other treatment available to prevent blindness.(Chronic DME). Trying to educate newbies is a whole different story. The only advice any of us can give is to do your DD and decide for yourself. Been holding for 5 yrs. and have seen the swings from 7 to under 1. In a holding pattern right now with everyone waiting for news. Believe still a buying opportunity at this level cause when Sept hits it is gonna jump. JMHO.

      • 1 Reply to eyeknow12
      • Right on Eyeknow, nice reply to Mo's points. Perhaps other catalysts on the fall horizon might be pending; 1). licensing of tethadur platform for a billion dollar drug such as Lucentis or Eylea to sustain release over 6 months( instead of monthly or every 6 weeks). 2). pIII Uveitis trial clarity and updates. This is PSDV's entirely, they will be able to market the whole program, and upwards of 200K patients are in serious need of a viable therapy in the US alone and the FDA loves it already.
        In ending the license deal for Tethadur alone will double the sp, FDA approval will double it again. A buyout will double that, because any of the drug companies looking for a sustained release platform won't want to share on the "healthy" split. It's a sprint to the finish line when it comes to this little company and it's peers. PSDV will win.

4.50+0.10(+2.27%)10:44 AMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.